FAM111B and ovarian cancer: To assess the impact of FAM111B on the migratory and invasive properties of ovarian cancer cells, we conducted Transwell assays; and our results indicated a notable decrease in the migratory capacity of FAM111B-silenced cells compared to the shCtrl group (Fig. 2A and B).